TY - JOUR
T1 - Advances in the treatment of Hodgkin lymphoma
T2 - Current and future approaches
AU - Ullah, Fauzia
AU - Dima, Danai
AU - Omar, Najiullah
AU - Ogbue, Olisaemeka
AU - Ahmed, Sairah
N1 - Publisher Copyright:
Copyright © 2023 Ullah, Dima, Omar, Ogbue and Ahmed.
PY - 2023
Y1 - 2023
N2 - Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic, immunophenotypic, and clinical features. It represents approximately one-tenth of lymphomas diagnosed in the United States and consists of two subtypes: classical Hodgkin’s lymphoma (cHL), which accounts for majority of HL cases, and nodular lymphocyte predominant Hodgkin lymphoma represent approximately 5% of Hodgkin lymphoma cases. From this point, we will be focusing on cHL in this review. In general, it is considered a highly curable disease with first-line chemotherapy with or without the addition of radiotherapy. However, there are patients with disease that relapses or fails to respond to frontline regimens and the standard treatment modality for chemo sensitive cHL is high dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT). In recent years, targeted immunotherapy has revolutionized the treatment of cHL while many novel agents are being explored in addition to chimeric antigen receptor (CAR) T-cell therapy which is also being investigated in clinical trials as a potential treatment option.
AB - Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic, immunophenotypic, and clinical features. It represents approximately one-tenth of lymphomas diagnosed in the United States and consists of two subtypes: classical Hodgkin’s lymphoma (cHL), which accounts for majority of HL cases, and nodular lymphocyte predominant Hodgkin lymphoma represent approximately 5% of Hodgkin lymphoma cases. From this point, we will be focusing on cHL in this review. In general, it is considered a highly curable disease with first-line chemotherapy with or without the addition of radiotherapy. However, there are patients with disease that relapses or fails to respond to frontline regimens and the standard treatment modality for chemo sensitive cHL is high dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT). In recent years, targeted immunotherapy has revolutionized the treatment of cHL while many novel agents are being explored in addition to chimeric antigen receptor (CAR) T-cell therapy which is also being investigated in clinical trials as a potential treatment option.
KW - chemoimmunotherapy
KW - chimeric antigen receptor (CAR) T-cell therapy
KW - Classical Hodgkin lymphoma (cHL)
KW - hematopoietic stem cell transplant
KW - relapsed and refractory Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85150421635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150421635&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1067289
DO - 10.3389/fonc.2023.1067289
M3 - Review article
C2 - 36937412
AN - SCOPUS:85150421635
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1067289
ER -